Back to Results

Penumbra Inc (PEN)

Featured in Overvalued Stocks

Penumbra, Inc. is a healthcare company focused on medical device design, development, manufacturing, and commercialization in the United States and international markets. Its product portfolio includes systems for thrombectomy, such as the Indigo System, Lightning Flash, Lightning Bolt 7, CAT RX, and the Penumbra System, along with a range of access products and catheters sold under brands including Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25, MIDWAY, and PX SLIM. The company also develops neuro embolization products for aneurysms and other complex lesions, peripheral embolization platforms, and neurosurgical tools such as the Artemis Neuro Evacuation Device. Penumbra sells its products through direct sales teams and distributors. Founded in 2004, the company is based in Alameda, California.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NYSE-PEN
$275.18
-13.4% Downside
Fair
$362.54
14.1% Upside
Fair
Great
—
—
—
0.0%
August 4, 2026
73.1x
8.5x
8.6x
12.508 B
12.098 B
1.7%
97.2%
19.8
—
124.4%
Send a message
Valuation • Fair Value

Penumbra Inc (NYSE-PEN) Fair Value by Valuation Model

Compare the primary fair value estimate for Penumbra Inc (NYSE-PEN) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

$275.18

Estimated downside of 13.4% versus the current market price.

Fair Value Confidence

High

Confidence level for the primary fair value estimate.

DCF Fair Value

$265.89

Discounted cash flow valuation reference.

Ben Graham Formula Value

$48.25

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

$284.47

Comparable-company valuation reference.

Analyst Price Target

$362.54

Analysts imply upside of 14.1%.

How to read these valuation models

Use this section to compare the primary fair value estimate for Penumbra Inc (NYSE-PEN) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Penumbra Inc (NYSE-PEN)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

1.454 B

Current operating scale indicator.

Revenue Forecast

1.59 B

Forward revenue estimate.

EBITDA

204 M

Current operating profitability reference.

EBITDA Forecast

291.8 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Penumbra Inc (NYSE-PEN) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Penumbra Inc (NYSE-PEN)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Great

Positive financial-health read.

Piotroski Score

6

Mid-range quality score.

Beneish M-Score

-2.67

No elevated caution signal from this screen.

Altman Z-Score

19.8

Relatively strong balance-sheet zone.

FCF / Net Income

124.4%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Penumbra Inc (NYSE-PEN). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Penumbra Inc (NYSE-PEN)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

August 4, 2026

Days to Earnings

14

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Penumbra Inc (NYSE-PEN), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Penumbra Inc (NYSE-PEN) Stock Forecast & Technical Outlook

Review Penumbra Inc (NYSE-PEN) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Penumbra Inc (NYSE-PEN) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Penumbra Inc (NYSE-PEN) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Neutral

The daily technical read for Penumbra Inc (NYSE-PEN) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Sell

The weekly technical read for Penumbra Inc (NYSE-PEN) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Penumbra Inc (NYSE-PEN) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Penumbra Inc (NYSE-PEN)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Hold

Based on the available recommendation mix, Penumbra Inc (NYSE-PEN) has a Hold consensus, with 2 buy, 13 hold and 0 sell recommendations in the current data set.

Buy 2
Hold 13
Sell 0
FAQ • Fast Investor Answers

Penumbra Inc (NYSE-PEN) Stock FAQ

Quick answers about Penumbra Inc (NYSE-PEN) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
$275.18
Estimated downside 13.4%
Valuation Rating
Overvalued
Estimated downside of 13.4%
Analyst Target
$362.54
Implied upside 14.1%
Financial Health
Great
Current financial-health read

The current fair value estimate for Penumbra Inc (NYSE-PEN) is $275.18. This implies an estimated downside of 13.4% versus the current market price.

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 13.4% versus the current market price.

The available analyst price target for Penumbra Inc (NYSE-PEN) is $362.54. The analyst target implies estimated upside of 14.1%.

The current financial health read for Penumbra Inc (NYSE-PEN) is Great. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Penumbra Inc (NYSE-PEN) is August 4, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Penumbra Inc (NYSE-PEN) is 73.1x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Penumbra Inc is 12.508 B.

The current enterprise value listed for Penumbra Inc is 12.098 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Penumbra Inc is NYSE-PEN, and the stock is listed on NYSE.

Penumbra Inc (NYSE-PEN) is listed on NYSE.

The current debt-to-total-capital ratio listed for Penumbra Inc is 1.7%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Penumbra Inc is 97.2%. Free float helps investors understand how much of the share base is available for public trading.

Similar Healthcare Equipment & Supplies Stocks on NYSE View more

Abbott Laboratories (ABT) Abbott Laboratories (ABT)
Stryker Corporation (SYK) Stryker Corporation (SYK)
Medtronic PLC (MDT) Medtronic PLC (MDT)
Boston Scientific Corp (BSX) Boston Scientific Corp (BSX)
Edwards Lifesciences Corp (EW) Edwards Lifesciences Corp (EW)
Becton Dickinson and Co (BDX) Becton Dickinson and Co (BDX)
Alcon AG (ALC) Alcon AG (ALC)
ResMed Inc (RMD) ResMed Inc (RMD)
Koninklijke Philips NV ADR (PHG) Koninklijke Philips NV ADR (PHG)
STERIS plc (STE) STERIS plc (STE)
Zimmer Biomet Holdings Inc (ZBH) Zimmer Biomet Holdings Inc (ZBH)
Solventum Corp (SOLV) Solventum Corp (SOLV)
Smith & Nephew SNATS Inc (SNN) Smith & Nephew SNATS Inc (SNN)
Baxter International Inc (BAX) Baxter International Inc (BAX)
Globus Medical (GMED) Globus Medical (GMED)
Glaukos Corp (GKOS) Glaukos Corp (GKOS)
Teleflex Incorporated (TFX) Teleflex Incorporated (TFX)
Bausch + Lomb Corp (BLCO) Bausch + Lomb Corp (BLCO)
Envista Holdings Corp (NVST) Envista Holdings Corp (NVST)
Haemonetics Corporation (HAE) Haemonetics Corporation (HAE)
Integer Holdings Corp (ITGR) Integer Holdings Corp (ITGR)
Butterfly Network, Inc (BFLY) Butterfly Network, Inc (BFLY)
Enovis Corp (ENOV) Enovis Corp (ENOV)
Inspire Medical Systems Inc (INSP) Inspire Medical Systems Inc (INSP)